Top

Reactions Weekly

Published in:

01-01-2024 | Rituximab | Case report

Mycophenolate-mofetil/rituximab

Impaired seroconversion

Published in: Reactions Weekly | Issue 1/2024

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Ferri C, et al. Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase. Journal of Translational Autoimmunity 7: Dec 2023. Available from: URL: https://dx.doi.org/10.1016/j.jtauto.2023.100212

Title: Mycophenolate-mofetil/rituximab
Impaired seroconversion
Publication date: 01-01-2024
Publisher: Springer International Publishing
Keywords: Rituximab
Rituximab
Systemic Sclerosis
Mycophenolate Mofetil
Published in: Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-024-52316-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Mycophenolate-mofetil/rituximab

Impaired seroconversion

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2024

Minoxidil

Guanfacine overdose

Adalimumab/betamethasone

Betamethasone/fusidic-acid/econazole/triamcinolone

Dexamethasone/Varicella zoster virus vaccine live

BBIBP-CorV